

United States Patent [19] Cohen

- [11]Patent Number:5,814,570[45]Date of Patent:Sep. 29, 1998
- [54] NONWOVEN BARRIER AND METHOD OF MAKING THE SAME
- [75] Inventor: Bernard Cohen, Berkeley Lake, Ga.
- [73] Assignee: Kimberly-Clark Worldwide, Inc., Neenah, Wis.
- [21] Appl. No.: 648,451
- [22] Filed: May 15, 1996

96/00093 1/1996 WIPO .

OTHER PUBLICATIONS

J. van Turnhout: Topics in Applied Physics, vol. 33, Chapter 3 "Thermally Stimulated Discharge of Electrets", pp. 81–215 (1980). J. van Turnhout: Thermally Stimulated Discharge of Polymer Electrets, Chapter 1, pp. 1–24 (1975). G.M. Sessler: Electronic Properties of Polymers, Chapter 3 "Charge Storage", pp. 59–107. Database WPI, Week 8324, Derwent Publications Ltd., London, GB; AN 83–57499K & JP,A, 58 076 118 (Koken KK), 9 May 1983, See Abstract. Database WPI, Section Ch, Week 8428, Derwent Publications Ltd., London, GB; Class A87, AN 84–173431, XP002008760, & JP,A,59 094 621 (Unitika KK), 31 May 1984, see abstract. Patent Abstracts of Japan, vol. 10, No. 71 (C-334), 20 March 1986 & JP,A,60 209220 (Kouken K.K.), 21 Oct. 1985, see abstract. Patent Abstracts of Japan, vol. 6, No. 191 (C–127), 30 Sep. 1982 & JP,A,57 105217 (Nitta K.K.), 30 Jun. 1982, see abstract & Chemical Abstracts, vol. 97, No. 26, 27 Dec. 1982, Columbus, Ohio, US; abstract No. 218901, "Fibrous" Filtering Material", see abstract. Patent Abstracts of Japan, vol. 11, No. 315 (C–451), 14 Oct. 1987 & JP,A,62 102809 (Mitsui Petrochem. Ind. Ltd.), 13 May 1987, see abstract & Database WPI, Section Ch, Week 8725, Derwent Publications Ltd., London, GB; Class A12, AN 87–172842 & JP,A,62 102 809 (Mitsui Petrochem. Ind. Co. Ltd.), 13 May 1987, see abstract. Journal of Electrostatics, vol. 21, 1988, Amsterdam NL, pp. 81-98, XP002012022, P. A. Smith & G. C. East: "Generation of Triboelectric Charge in Textile Fibre Mistures, and their use as Air Filters", see document. Database WPI, Section Ch, Week 8930, Derwent Publications, Ltd., London, GB; Class A94, AN 89-217687 XP002005648 & JP,A,01 156 578 (Showa Denko), 20 Jun. 1989, See Abstract.

Related U.S. Application Data

[51]	Int. Cl. ⁶	
[52]	U.S. Cl.	442/346 ; 204/164; 442/340;
		442/351; 442/382; 428/903
[58]	Field of Search	442/340 346

[56] **References Cited**

U.S. PATENT DOCUMENTS

Re. 30,782	10/1981	van Turnhout	264/22
Re. 31,285	6/1983	van Turnhout et al	55/155
Re. 32,171	6/1986	van Turnhout	55/155

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

11884526/1985CanadaA41D13/00012585111/1984European Pat. Off.D21C9/00

0 120 00 1		
0 156 160	10/1985	European Pat. Off A61L 15/00
0 391 725	4/1989	European Pat. Off
0 334 829	9/1989	European Pat. Off
0 337 662	10/1989	European Pat. Off
0 375 234	6/1990	European Pat. Off
0391725	10/1990	European Pat. Off
0 444 671	9/1991	European Pat. Off
0 462 574	12/1991	European Pat. Off
0 550 029	12/1991	European Pat. Off
$0\ 478\ 011$	4/1992	European Pat. Off A61F 13/15
0 497 072	8/1992	European Pat. Off A61F 13/15
0 520 798	12/1992	European Pat. Off D04H 1/42
0550029	7/1993	European Pat. Off
0 575 629	12/1993	European Pat. Off
0 576 738	1/1994	European Pat. Off A61F 13/15
0 594 123	4/1994	European Pat. Off
$1 \ 084 \ 015$	9/1957	Germany 156/276
44 47 152	7/1995	Germany A61L 15/60
58-076118	7/1958	Japan .
62-053719	8/1987	Japan .
62-074423	9/1987	Japan .
1-246413	10/1989	Japan .
5-064713	3/1993	Japan .
2 026 379	2/1980	United Kingdom D06M 9/00
2 242 142	9/1991	United Kingdom B03C 3/28
WO8103265	11/1981	WIPO .
90/11784	10/1990	WIPO .
91/08254	6/1991	WIPO .
92/16681	10/1992	WIPO D04H 1/42
93/06168	4/1993	WIPO .
93/09156	5/1993	WIPO C08G 8/18
94/00166	1/1994	WIPO .
94/01068	1/1994	WIPO .
95/05232	2/1995	WIPO .
95/05501	2/1995	WIPO .
95/22646	8/1995	WIPO .

An Introduction to Electrostatic Separation, Technical Bulletin, Bulletin 8570, Carpco, Inc.

Electrostatic Separation of Mixed Granular Solids by Oliver C. Ralston, Elsevier Publishing Company, 1961, Chapter IV, "Applications of Electrostatic Separation", pp. 134–234. "Bonding Process", IBM Technical Disclosure Bulletin, vol. 14, No. 12, May 1972.

USSN 08/242,948 filed May 16, 1994 entitled "Nonwoven Absorbent Polymeric Fabric Exhibiting Improved Fluid Management And Methods For Making The Same".

Primary Examiner—James J. Bell Attorney, Agent, or Firm—David J. Alexander; Jones & Askew, LLP

[57] **ABSTRACT**

A ethylene oxide sterilizable nonwoven material which is subjected to charging, and more particularly electrostatic charging is provided. The nonwoven materials may include laminate nonwovens wherein one or more layers are subjected to charging. The nonwoven material(s) may also be treated with an antistatic material before or after subjecting the same to charging.

19 Claims, No Drawings

5,814,570 Page 2

U.S. PATENT DOCUMENTS

			4,363,682	12/1982
668,791	2/1901	Blake et al	4,363,723	12/1982
813,063	2/1906	Sutton et al	4,373,224	2/1983
859,998		Wentworth .	4,374,727	2/1983
924,032	-	Blake et al	4,374,888	2/1983
1,222,305		Kraus.	4,375,718	3/1983
1,297,159	-	Hedberg.	4,392,876	7/1983
1,355,477	_	Howell .	4,394,235	7/1983
2,106,865		Bantz et al 209/127	4,411,795	10/1983
2,217,444		Hill	4,430,277	2/1984
		Oglesby 117/17	4,443,513	4/1984
2,378,067	-	Cook, Jr	4,443,515	4/1984
2,398,792	-	Johnson	4,451,589	5/1984 6/108/
		Miller 117/17 Sittel 154/1.7	4,455,195 4,455,237	6/1984 6/1984
3,012,668		Fraas	4,456,648	6/1984
3,059,772		Baron	4,492,633	1/1985
/ /		Blatz	4,507,539	3/1985
3,281,347		Winder 204/168	4,513,049	4/1985
3,323,933	6/1967	Barford et al 117/17	4,514,289	4/1985
3,338,992	8/1967	Kinney 264/24	4,517,143	5/1985
3,341,007		Mayer et al 209/2	4,534,918	8/1985
3,341,394		Kinney 161/72	4,547,420	10/1985
3,380,584		Fulwyler	4,551,378	-
3,402,814		Morel et al. $209/127$	4,554,207	-
3,436,797 3,502,763		Graf et al 156/272.6 Hartmann 264/210	4,555,811 4,588,537	12/1985 5/1986
3,542,615		Dobo et al. $156/181$	4,592,815	6/1980
3,581,886		Singewald et al	4,594,626	
3,692,606		Miller et al 156/273.1	4,618,524	10/1986
3,692,618	-	Dorschner et al	4,622,259	11/1980
3,802,817		Matsuki et al 425/66	4,623,438	11/1986
3,821,021	6/1974	McMillan 117/135.5	4,626,263	12/1986
3,849,241	11/1974	Butin et al 161/169	4,652,282	-
3,855,046	-	Hansen et al 161/150	4,652,322	
		Proskow	4,657,639	4/1987
3,896,802		Williams 128/149	4,657,804	4/1987 5/1087
3,907,604 3,909,009		Prentice	4,663,220 4,670,913	5/1987 6/1987
3,962,386		Driscoll	4,671,943	6/198
3,979,529	-	Rebentisch et al	4,677,017	6/198
3,998,916		van Turnhout	4,689,241	8/198
4,011,067		Carey, Jr 55/354	4,699,823	10/198
4,013,816		Sabee et al 428/288	4,705,151	11/1987
4,035,164	7/1977	Taylor .	4,707,398	11/1987
4,041,203		Brock et al 428/157	4,720,415	1/1988
4,058,724		McKinney et al	4,729,371	3/1988
		Weber 156/167	4,738,772	4/1988
4,091,140 4,096,289		Harrnon . Nicobwitz of al 427/22	4,739,882	4/1988 6/1089
4,103,062		Nischwitz et al	4,749,348 4,761,326	6/1988 8/1988
4,140,607	-	Kreiseimeier et al	4,789,504	12/1988
4,170,304	10/1979		4,795,668	1/1989
4,178,157	-	van Turnhout et al 55/155	4,797,201	1/1989
4,185,972		Nitta et al	4,797,318	1/1989
4,196,245	4/1980	Kitson et al 428/198	4,818,464	4/1989
4,208,366	6/1980	Kinney .	4,826,703	5/1989
4,209,563		Sisson 428/288	4,831,664	5/1989
4,215,682	-	Kubik et al 128/205.29	4,847,914	7/1989
4,223,677		Anderson	4,859,266	8/1989
· · ·		Beraud et al	4,863,785	
		Hood	4,863,983 4,874,399	
		Meitner	4,874,599	10/1989
		Stern	4,883,052	11/1989
		Balslev et al	4,886,527	
		Shinagawa et al	4,894,131	-
4,324,198		Muz 118/630	4,901,370	2/1990
4,340,563		Appel et al 264/518	4,904,174	2/1990
4,342,812		Selwood	4,917,942	4/1990
4,353,799	10/1982	Leonard	4,920,168	4/1990

4,357,234	11/1982	Inculet et al 209/127 B
4,363,682	12/1982	Thiebault .
4,363,723	12/1982	Knoll et al 209/128
4,373,224	2/1983	Bandai et al
4,374,727	2/1983	Takahashi et al 209/127 B
4,374,888	2/1983	Bornslaeger 428/198
4,375,718		Wadsworth et al 29/592
4,392,876	7/1983	Schmidt .
4,394,235	7/1983	Brandt et al
4,411,795	10/1983	Olson 210/679
4,430,277	2/1984	Lin.
4,443,513	4/1984	Meitner et al 422/195
4,443,515	4/1984	Atlas 428/224
4,451,589	5/1984	Morman et al 523/124
4,455,195	6/1984	Kinsley 162/13
4,455,237	6/1984	Kinsley 210/767
4,456,648		Adamse et al 428/283
4,492,633		Sandulyak et al
4,507,539	3/1985	Sando et al 219/121 PY
4,513,049	4/1985	Yamasaki et al
4,514,289	4/1985	Inculet 209/127.3
4,514,289 4,517,143	4/1985 5/1985	Inculet
4,514,289 4,517,143 4,534,918	4/1985 5/1985 8/1985	Inculet
4,514,289 4,517,143 4,534,918 4,547,420	4/1985 5/1985 8/1985 10/1985	Inculet
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378	4/1985 5/1985 8/1985 10/1985 11/1985	Inculet
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985	Inculet
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985	Inculet 209/127.3 Kisler . Forrest, Jr. . Krueger et al. 428/229 Carey, Jr. 428/198 Lee 428/288 Shimalla 2/51
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986	Inculet209/127.3Kisler.Forrest, JrKrueger et al.428/229Carey, Jr.428/198Lee428/288Shimalla2/51Klaase et al.264/22
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537 4,592,815	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986 6/1986	Inculet209/127.3Kisler.Forrest, JrKrueger et al.428/229Carey, Jr.428/198Lee428/288Shimalla2/51Klaase et al.264/22Nakao204/165
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537 4,592,815 4,594,626	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986 6/1986 6/1986	Inculet 209/127.3 Kisler . Forrest, Jr. . Krueger et al. 428/229 Carey, Jr. 428/198 Lee 428/288 Shimalla 2/51 Klaase et al. 264/22 Nakao 204/165 Frangesh .
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537 4,592,815 4,594,626 4,618,524	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986 6/1986 6/1986 10/1986	Inculet
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537 4,592,815 4,594,626 4,618,524 4,618,524	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986 6/1986 6/1986 10/1986 10/1986	Inculet 209/127.3 Kisler . Forrest, Jr. . Krueger et al. 428/229 Carey, Jr. 428/198 Lee 428/288 Shimalla 2/51 Klaase et al. 264/22 Nakao 204/165 Frangesh . Groitzsch et al. 428/198 McAmish et al. 428/171
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537 4,592,815 4,592,815 4,594,626 4,618,524 4,622,259 4,623,438	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986 6/1986 6/1986 10/1986 11/1986 11/1986	Inculet 209/127.3 Kisler . Forrest, Jr. . Krueger et al. 428/229 Carey, Jr. 428/198 Lee 428/288 Shimalla 2/51 Klaase et al. 264/22 Nakao 204/165 Frangesh . Groitzsch et al. 428/198 McAmish et al. 428/171 Felton et al. 204/168
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537 4,592,815 4,592,815 4,594,626 4,618,524 4,622,259 4,623,438 4,626,263	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986 6/1986 6/1986 10/1986 11/1986 11/1986 11/1986	Inculet 209/127.3 Kisler . Forrest, Jr. . Krueger et al. 428/229 Carey, Jr. 428/198 Lee 428/288 Shimalla 2/51 Klaase et al. 264/22 Nakao 204/165 Frangesh . Groitzsch et al. 428/198 McAmish et al. 428/171 Felton et al. 204/168 Inoue et al. 204/168
4,514,289 4,517,143 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537 4,592,815 4,592,815 4,594,626 4,618,524 4,622,259 4,623,438 4,626,263 4,652,282	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986 6/1986 6/1986 10/1986 11/1986 11/1986 11/1986 3/1987	Inculet 209/127.3 Kisler Forrest, Jr. Forrest, Jr. 428/229 Carey, Jr. 428/198 Lee 428/288 Shimalla 2/51 Klaase et al. 264/22 Nakao 204/165 Frangesh 300 Groitzsch et al. 428/198 McAmish et al. 428/171 Felton et al. 204/168 Inoue et al. 204/165
4,514,289 4,517,143 4,534,918 4,534,918 4,547,420 4,551,378 4,554,207 4,555,811 4,588,537 4,592,815 4,592,815 4,594,626 4,618,524 4,622,259 4,623,438 4,622,259 4,623,438 4,652,282 4,652,322	4/1985 5/1985 8/1985 10/1985 11/1985 11/1985 12/1985 5/1986 6/1986 6/1986 10/1986 10/1986 11/1986 11/1986 11/1986 3/1987 3/1987	Inculet 209/127.3 Kisler . Forrest, Jr. . Krueger et al. 428/229 Carey, Jr. 428/198 Lee 428/288 Shimalla 2/51 Klaase et al. 264/22 Nakao 204/165 Frangesh . Groitzsch et al. 428/198 McAmish et al. 428/171 Felton et al. 204/168 Inoue et al. 204/168

4,657,639	4/1987	Mahadevan et al.
4,657,804	4/1987	Mays et al 428/212
4,663,220	5/1987	Wisneski 428/221
4,670,913	6/1987	Morell et al 2/227
4,671,943	6/1987	Wahlquist .
4,677,017	6/1987	DeAntonis et al 428/214
4,689,241	8/1987	Richart et al 427/28
4,699,823	10/1987	Kellenberger et al 428/219
4,705,151	11/1987	Eldridge.
4,707,398	11/1987	Boggs 428/224
4,720,415	1/1988	VanderWielen et al 428/152
4,729,371	3/1988	Krueger et al 128/206.19
4,738,772	4/1988	Giesfeldt 209/2
4,739,882	4/1988	Parikh et al
4,749,348	6/1988	Klaase et al 425/174.8
4,761,326	8/1988	Barnes et al 428/219
4,789,504	12/1988	Ohmori et al
4,795,668	1/1989	Krueger et al 428/174
4,797,201	1/1989	Kuppers et al 209/127.4
4,797,318	1/1989	Brooker et al
4,818,464	4/1989	Lau
4,826,703	5/1989	Kisler 427/466
4,831,664	5/1989	Suda .
4,847,914	7/1989	Suda .
4,859,266	8/1989	Akasaki et al 156/273.1
4,863,785	9/1989	Berman et al 428/218
4,863,983	9/1989	Johnson et al 524/140
4,874,399	10/1989	Reed et al 55/2
4,874,659	10/1989	Ando et al 428/221
4,883,052	11/1989	Weiss et al
4,886,527	12/1989	Fottinger et al 55/156
4,894,131	1/1990	Jacobs et al
4,901,370	2/1990	Suda .
4,904,174	2/1990	Moosmayer et al
4,917,942	4/1990	Winters 428/286
4,920,168	4/1990	Nohr et al 524/188

5,814,570 Page 3

4,944,854	7/1990	Felton et al 204/168
4,948,515	8/1990	Okumura et al 210/748
4,948,639	8/1990	Brooker et al 428/35.2
4,960,820	10/1990	Hwo 524/528
4,965,122	10/1990	Morman 428/225
4,983,677	1/1991	Johnson et al 525/127
5,012,094	4/1991	Hamade .
5,021,501	6/1991	Ohmori et al 524/544
5,032,419	7/1991	Lamirand et al 427/470
5,035,941	7/1991	Blackburn 428/286
5,051,159	9/1991	Togashi et al 204/165
5,055,151	10/1991	Duffy .
5,057,710	10/1991	Nishiura et al

5,238,733	8/1993	Joseph et al 428/284
5,244,482	9/1993	Hassenboehler, Jr 55/528
5,246,637	9/1993	Matsuura et al
5,247,072	9/1993	Ning et al 536/97
5,254,297	10/1993	Deeds .
5,256,176	10/1993	Matsuura et al 55/528
5,257,982	11/1993	Cohen et al 604/378
5,264,276	11/1993	McGregor et al 428/252
5,284,703	2/1994	Everhart et al 428/283
5,286,326	2/1994	Greve 156/272.4
5,294,482	3/1994	Gessner .
5,306,534	4/1994	Bosses 428/35.2

5,062,158	11/1991	Oka et al 2/46
5,077,468	12/1991	Hamade .
5,090,975	2/1992	Requejo et al
5,110,620	5/1992	Tani et al 427/40
5,112,048	5/1992	Deeds .
5,112,677	5/1992	Tani et al
5,118,942	6/1992	Hamade
5,135,724	8/1992	Dinter et al
5,138,971	8/1992	Nakajima et al
5,143,767	9/1992	Matsuura et al
5,149,335	9/1992	Kellenberger et al 604/372
5,156,902	10/1992	Pieper et al 604/370
5,165,979	11/1992	Watkins et al 428/113
5,169,706	12/1992	Collier, IV et al 428/152
5,173,356	12/1992	Eaton et al 428/219
5,178,932	1/1993	Perkins et al 428/198
5,183,701	2/1993	Jacobs et al 428/229
5,188,885	2/1993	Timmons et al 428/198
5,204,174	4/1993	Daponte et al 428/286
5,206,061	4/1993	Ando et al 428/34.7
5,213,881	5/1993	Timmons et al 428/224
5,213,882	5/1993	Sassa et al 428/224
5,226,992	7/1993	Morman 156/62.4
5,230,727	7/1993	Pound et al 55/492

5,308,674	5/1994	Zafiroglu	428/102
5,308,691	5/1994	Lim et al	428/286
5,336,545	8/1994	Morman	428/152
5,350,620	9/1994	Sundet et al	428/172
5,389,202	2/1995	Everhart et al	162/103
5,397,413	3/1995	Trimble et al	156/167
5,401,446	3/1995	Tsai	. 264/22
5,407,581	4/1995	Onodera et al	210/654
5,409,766	4/1995	Yuasa et al	428/224
5,411,576	5/1995	Jones et al	95/57
5,436,033	7/1995	Mino et al	
5,436,066	7/1995	Chen	428/288
5,441,550	8/1995	Hassenboehler, Jr	. 55/486
5,443,606	8/1995	Hassenboehler, Jr	. 55/486
5,455,108	10/1995	Quincy et al	428/266
5,456,972	10/1995	Roth et al	428/224
5,464,688		Timmons et al	
5,468,428		Hanschen et al	
5,472,481		Jones et al	96/15
5,482,765	1/1996	Bradley et al	
5,486,411	1/1996	Hassenboehler, Jr. et al	428/286
5,491,022		Smith	
5,493,117		Tamaki et al	
5 496 507	3/1006	Angadiiyand et al	264/423

Ι

NONWOVEN BARRIER AND METHOD OF MAKING THE SAME

This application is a continuation of application Ser. No. 08/266,293 entitled "IMPROVED NONWOVEN BAR- 5 RIER AND METHOD OF MAKING THE SAME" and filed in the U.S. Patent and Trademark Office on Jun. 27, 1994, now abandoned. The entirety of this Application is hereby incorporated by reference.

FIELD OF THE INVENTION

The present invention is directed to bacterial barrier fabrics. More particularly, the present invention is directed to nonwoven bacterial barrier fabrics for use as, for example, sterilization wrap, surgical draping, surgical gowns, cover 15 garments, such as over-suits, and the like.

2

applications, such as personal protective equipment applications, whose designers require both fabric comfort and filtration efficiency. Other personal protective equipment applications include, but are not limited to, laboratory applications, clean room applications, such as semiconductor manufacture, agriculture applications, mining applications, and environmental applications.

Therefore, there is a need for garment materials and methods for making the same which provide improved breathability and comfort as well as improved filtration efficiency. Such improved materials and methods are provided by the present invention and will become more apparent upon further review of the following specification and claims.

BACKGROUND OF THE INVENTION

As is generally known, surgical gowns, surgical drapes, surgical face masks and sterile wrap (hereinafter collectively "surgical articles") have been designed to greatly reduce, if not prevent, the transmission through the surgical article of liquids and/or airborne contaminates. In surgical procedure environments, such liquid sources include the gown wearer's perspiration, patient liquids, such as blood and life support liquids such as plasma and saline. Examples of airborne contaminates include, but are not limited to, biological contaminates, such as bacteria, viruses and fungal spores. Such contaminates may also include particulate material such as, but not limited to, lint, mineral fines, dust, skin squares and respiratory droplets. A measure of a fabrics ability to prevent the passage of such airborne materials is sometimes expressed in terms of "filtration efficiency".

Many of these surgical articles were originally made of cotton or linen and were sterilized prior to their use in the $_{35}$

SUMMARY OF THE INVENTION

In response to the above problems encountered by those of skill in the art, the present invention provides an ethylene oxide sterilizable polymer web, such as, for example, a nonwoven fabric. The webs of the present invention are formed by subjecting a portion of the web to charging, and more particularly to electrostatic charging, and then ethylene oxide sterilizing the web. The web may be subjected to charging followed by ethylene oxide sterilization or ethylene oxide sterilization followed by charging. The web may also be treated with an antistatic material before or after subjecting the web to charging.

The above web may further include a second web in a 30 juxtaposed relationship to the first web. The second web may be formed from polymer fibers wherein a portion of these fibers may be subjected to charging. An antistatic treatment may also be present about portions of the second web.

operating room. Such surgical articles fashioned from these materials, however, permitted transmission or "strikethrough" of various liquids encountered in surgical procedures. In these instances, a path was established for transmission of biological contaminates, either present in the liquid or subsequently contacting the liquid, through the surgical article. Additionally, in many instances surgical articles fashioned from cotton or linen provide insufficient barrier protection from the transmission therethrough of airborne contaminates. Furthermore, these articles were costly, and, of course, laundering and sterilization procedures were required before reuse.

Disposable surgical articles have largely replaced linen surgical articles. Advances in such disposable surgical articles include the formation of such articles from totally $_{50}$ liquid repellent fabrics which prevent strike-through. In this way, biological contaminates carried by liquids are prevented from passing through such fabrics. However, in some instances, surgical articles formed from nonporous films, while being liquid and airborne contaminate impervious, 55 may retain body heat and moisture and thus may become over a period of time, uncomfortable to wear. In some instances, surgical articles fashioned from liquid repellent fabrics, such as fabrics formed from nonwoven polymers, sufficiently repel liquids and are more breathable 60 and thus more comfortable to the wearer than nonporous materials. However, these improvements in comfort and breathability provided by such nonwoven fabrics have generally occurred at the expense of barrier properties or filtration efficiency.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are compositions, and methods of making the same, which improved both the airborne contaminate barrier and filtration efficiency of a web. The web of the present invention may be formed from polymer fibers, films, foams or a combination thereof. The films and foams may be porous or non-porous.

Among the applications for such compositions and methods are included, but not limited to, applications requiring sterilizable, breathable materials having high airborne contaminate barrier properties. Such materials have application in surgical articles, such as gowns, drapes, sterile wrap and face mask, as well as other non-surgical applications such as agriculture, mining, clean room and environmental.

Polymers, and particularly thermoplastic polymers, are well suited for the formation of webs which are useful in the practice of the present invention. Nonwoven webs useful in present invention can be made from a variety of processes including, but not limited to, air laying processes, wet laid processes, hydroentangling processes, spunbonding, meltblowing, staple fiber carding and bonding, and solution spinning. The materials suitable for forming webs of the present invention include a variety of dielectric materials such as, but not limited to, polyesters, polyolefins, nylon and copolymers, polymer blends and bi-component polymers of these materials. In the case of nonwoven webs formed from 65 fibers, the fibers may be relatively short, staple length fibers, typically less than 3 inches, or longer more continuous fibers such as are produced by a spunbonding process.

While the focus thus far has been directed to surgical articles, there are many other garment or over-garment

3

It has been found that nonwoven webs formed from polyolefin-based fibers are particularly well-suited for the above applications. Examples of such nonwovens are the polypropylene nonwovens produced by Kimberly-Clark Corporation. And more particularly, a three layered the 5 spunbond, meltblown, spunbond material (SMS) produced by Kimberly-Clark Corporation.

This spunbond, meltblown, spunbond material may be made from three separate layers which are laminated to one another. Such a method of making this laminated material is 10 described in commonly assigned U.S. Pat. No. 4,041,203 to Brock et al which is herein incorporated by reference. Alteratively, the spunbond, meltblown, spunbond material may be made by first forming a spunbond, meltblown laminate. The spunbond, meltblown laminate is formed by 15 applying a layer of meltblown on to a layer of spunbond. The second layer of spunbond is then applied to the meltblown side of the previously formed spunbond, meltblown laminate. Generally, the two outer layers provide the nonwoven fabric with strength while the inner layer provides barrier ²⁰ properties. Suitable webs may be formed from a single layer or multiple layers. In the case of multiple layers, the layers are generally positioned in a juxtaposed or surface-to-surface relationship and all or a portion of the layers may be bound to adjacent layers. In the case of a nonwoven web, the nonwoven web may be formed from a plurality of separate nonwoven webs wherein the separate nonwoven webs may be formed from single or multiple layers. In those instances where the web includes multiple layers, the entire thickness 30 of the web may be subjected to charging or individual layers may be separately subjected to charging and then combined with other layers in a juxtaposed relationship to form the finished web.

Process Parameters	Set Point
A. PRECO	ONDITIONING
Temperature Relative Humidity	115° F. 63%
Holding time	18 hours RILIZATION
Chamber Temperature	130.0 F.
during exposure	130.0 F.
Chamber Temperature at all other times	
Initial Evacuation	1.2" Absolut

There are many well known methods of subjecting a ³⁵ material to charging, and particularly electrostatic charging. These well known methods include, for example, thermal, liquid-contact, electron beam and corona discharge methods. The method used for electrostatically charging the $_{40}$ materials discussed in the Examples 1 and 2 (below) is the technique disclosed in U.S. patent application No. 07/958, 958 filed Oct. 9, 1992 which is assigned to the University of Tennessee, and is herein incorporated by reference. This technique involves subjecting a material to a pair of electrical fields wherein the electrical fields have opposite polarities. Sterilization of the web may also be accomplished by ethylene' oxide sterilization. In those instances when it is desired to sterilize surgical instruments by ethylene oxide, 50the surgical instruments may be wrapped in a nonwoven web. The entire package may then be subjected to an ethylene oxide sterilization cycle. When the ethylene oxide sterilization cycle is completed, the instruments, still wrapped, are then removed from the ethylene oxide steril- 55 izing equipment and are stored in the wrapping material until-needed. When needed, the wrapping web is removed making the instruments available for handling. The ethylene oxide sterilization cycle may vary dependent upon type of sterilizer and the size/quantity of the items 60 being sterilized. In the Examples described below, ethylene oxide sterilization was accomplished by using either a RSSA Chamber J88-39 or J88-59, made by Vacu Dyne, Ill. Generally, the ethylene oxide sterilization cycle includes a preconditioning phase, a sterilization phase and a de-gassing 65 phase. The process parameters for each of these phases are provided below.

Leak Test 1.2" Absolute Leak Test Dwell 5 minutes Nitrogen Dilution 3.2" Absolute Evacuation 1.2" Absolute Humidity Injection 2.9" Absolute Pressure Increase to Humidification Dwell 30 minutes Time ETC Injection Pressure 15" Absolute Time to inject gas NA Cycle Exposure 2 hours Exposure Pressure 15" Absolute Exposure Temperature 130.0 F. 6.0" Absolute 1st Re-evacuation 1st Nitrogen Inbleed 50.0" Absolute 2nd Re-evacuation 1.6" Absolute 2nd Nitrogen Inbleed 50.0" Absolute 3rd Re-evacuation 1.6" Absolute 3rd Nitrogen Inbleed 50.0" Absolute 4th Re-evacuation 1.6" Absolute Air Inbleed To Atmospheric Pressure C. DEGASSING PARAMETERS

Degassing Time	24.0 hours
Degassing Temperature	130° F.

In those instances where the web is used in or around flammable materials or static charge build-up and/or discharge is a concern, the web may be treated with any number of antistatic materials. In these instances, the antistatic material may be applied to the web by any number of well known techniques including, but not limited to dipping the web into a solution containing the antistatic material or by spraying the web with a solution containing the antistatic material. In some instances the antistatic material may be applied to both the external surfaces of the web and the bulk of the web. In other instances, the antistatic material may be applied to portions of the web, such as a selected surface or surfaces thereof.

Of particular usefulness as an antistatic material is an alcohol phosphate salt product known as ZELEC® and available from the Du Pont Corporation. The web may be treated with the antistatic material either before or after subjecting the web to charging. Furthermore, some or all of the material layers may be treated with the antistatic material. In those instances where only some of the material layers are treated with antistatic material, the non-treated layer or layers may be subjected to charging prior to or after combining with the antistatic treated layer or layers.

To demonstrate the attributes of the present invention, the following Examples are provided.

EXAMPLE 1

Kimberly-Clark manufactures a series of single sheet laminate nonwoven web materials made from three layers of fibrous material, i.e., spunbond-meltblown-spunbond (SMS) layers. These materials are available in a variety of basis weights. The two nonwoven webs used in these Examples

5

were such single sheet laminate materials sold by Kimberly-Clark. Each of the nonwoven webs had a basis weight of 2.2 osy (ounces per square yard). Both spunbond layers had a basis weight of 0.85 osy and the meltblown layer had a basis weight of 0.50 osy. One of the nonwoven webs was a 5 ZELEC® treated laminate and is sold by Kimberly-Clark under the mark KIMGUARD[™] Heavy Duty Sterile Wrap and is designated in Table I as "KIMGUARD[™]".

The other nonwoven web, designated in Table I as "RSR" also had a basis weight of 2.2 osy but was not treated with ¹⁰ an antistatic material. Both spunbond layers had a basis weight of 0.85 osy and the meltblown layer had a basis weight of 0.50 osy.

6

non-electret-treated KIMGUARD[™] fabric samples which were ethylene oxide-sterilized ("KIMGUARD[™]/EO").

The second category reported in Table II is "Microbial Challenge BFE". This category includes the average BFEs for the KIMGUARDTM samples.

The Microbial Challenge BFE procedure utilized a six port exposure chamber. Five of the ports accommodated five separate samples. The challenge control filter material was positioned in the sixth port. Three conditions were maintained in the microbial challenge test. These were: first, a 2.8 LPM (Liters Per Minute) flow rate through each of the ports; second, an exposure time of fifteen minutes followed by a chamber exhaust of fifteen minutes, and; third, a microbial challenge that results in 1×10^6 CFU's (Colony Forming) Units) per port. Bacillus subtilis ss globigii spores, pur-15 chased from Amsco (Part No. NA-026, P-764271-022) were used to make the working spore suspension of 1×10^6 CFUs per port recovery. The value reported is an expression of the reduction of number of colony forming units (CFUs) or bacteria passing through a sample compared to the number CFUs passing through the challenge control filter material. This value was derived by subtracting the number of CFUs passing through a sample from the number of CFUs passing through the challenge control filter material. The difference in the number of CFUs passing through these materials is then divided by the number of CFUs passing through the challenge filter material and then multiplied by 100 to convert to percent.

The method used to subject these webs to electrostatic charging (electret treating) is described in the above referenced U.S. patent application No. 07/958,958.

The surface charge for both KIMGUARD[™] and RSR fabrics were analyzed and the data reported in Table I. The charge data for each side of these fabrics was recorded for both before ("AS RECEIVED") and after charging ("ELECTRETED"). Charge data were also recorded for ethylene oxide sterilized fabric samples which were first charged and then ethylene oxide sterilized ("AFTER EO TREATMENT"). As noted in Example 1, the KIM-25 GUARDTM samples were treated with ZELECTM and the RSR samples were not. Charge measurements were taken at 36 separate surface locations on each sample. For the categories, i.e., "AS RECEIVED" and "ELECTRETED", the KIMGUARDTM and RSR samples were each single large sheets of material. Each such sheets were then portioned into several smaller samples. Sterilization and filtration data reported in Example 2 were derived from these smaller samples.

Charge measurements reported are averaged values of positive (+) or negative (-) volts per cm². The equipment used to measure charge was an Electrostatic Voltmeter (Trek Model 344, Trek, Inc, Median, N.Y.).

TABLE II

Sample	Nelson BFE	Microbial Challenge BFE
KIMGUARD ®/Electret/EO	97.51 +/- 0.39	96.44 +/- 4.51
KIMGUARD ®/EO	89.96 +/- 1.04	79.04 +/- 6.50

TABLE I

				After EO Treatment		
Material	Side	As Received	Elect- reted	Sam- ple 1	Sam- ple 2	Sam- ple 3
KIMGUARD ® (ZELEC ®) RSR (Non-ZELEC ®)	A B A B	-2.8 +1.6 -61 -87	-125 -15 +272 -432	-4.2 24.1 -89 -90	27.2 -5.4 -130 -46	-138 +54

Table III summarizes the average Nelson BFE and the Microbial Challenge BFE categories for the RSR nonwoven materials. The procedures for both the Nelson BFE and identical to the Nelson BFE and Microbial Challenge BFE procedures describe above. "RSR/Electret/EO" stands for RSR electret-treated then ethylene oxide-treated samples. "RSR/Electret" stands for RSR electret-treated samples. "RSR/EO" stands for RSR ethylene oxide-sterilized samples. 15 samples of each class of RSR material described above were analyzed and the results averaged.

TABLE III

As illustrated by the above data, the ethylene oxide ⁵⁰ sterilization process generally diminished the overall surface charge for both the electret treated KIMGUARD[™] and the RSR material.

EXAMPLE 2

A summary of the average bacterial filtration efficiency (BFE) test results and standard deviation (SD) are reported for the two categories investigated for KIMGUARDTM in Table II. The first category, reported in Table II is the "Nelson BFE". "Nelson BFE" stands for Nelson Laborato- 60 ry's (Salt Lake City, Utah) bacterial filtration efficiency test. The procedure used to determine these BFEs is described in Nelson Laboratories' Protocol No. ARO/007B in accordance with MIL Spec 36954C, 4.4.1.1.1 and 4.4.1.2. This category includes the average BFE for 11 KIMGUARDTM 65 fabric samples which were electret-treated then ethylene oxide-sterilized ("KIMGUARDTM/Electret/EO") and 11

50 -	Sample	Nelson BFE	Microbial Challenge BFE		
	RSR/Electret/EO	96.92 +/- 0.91	97.56 +/- 0.83		
	RSR/Electret	95.75 +/- 0.60	98.91 +/- 0.64		
	RSR/EO	79.73 +/- 3.20	79.82 +/- 5.96		

55 Example 2 demonstrates that barrier properties of an ethylene oxide sterilizable material are improved when such material is first subjected to charging, and particularly electrostatic charging, and then ethylene oxide sterilized as compared to the same material which is not subjected to 60 charging prior to ethylene oxide sterilization. It will be further observed that the decrease in the surface charge which occurred after ethylene oxide sterilization (Table I) did not significantly affect the barrier properties of these materials.

While the invention has been described in detail with respect to specific embodiments thereof, it will be appreciated that those skilled in the art, upon attaining an under-

5

7

standing of the foregoing, may readily conceive of alterations to, variations of and equivalents to these embodiments. Accordingly, the scope of the present invention should be assessed as that of the appended claims and any equivalents thereto.

What is claimed is:

1. An ethylene oxide sterilized web wherein at least one portion of the web has been subjected to electrostatic charging.

2. The web of claim 1 wherein the web is formed from a 10 nonwoven material which comprises first and second non-woven webs joined together in juxtaposed relationship.

3. The web of claim 1 having a surface and wherein such surface has a negative charge and wherein the average negative surface charge on the surface is less than 100 15 volts/ cm^2 . 4. The web of claim 1 having a first and a second surface and wherein these surfaces have a negative charge and wherein the average negative surface charge on the first surface is less than 100 volts/ cm^2 and wherein the average 20 negative surface charge on the second surface is less than 100 volts/cm^2 . 5. The web of claim 1 having a surface and wherein such surface has a positive charge and wherein the average positive surface charge on the surface is less than 60 25 volts/ cm^2 . 6. The web of claim 1 containing an antistatic material. 7. An ethylene oxide sterilized nonwoven web laminate comprising:

8

at least one of the layers is subjected to electrostatic charging.

8. The nonwoven web of claim 7 wherein all three layers are subjected to electrostatic charging.

9. The nonwoven web of claim 8 wherein at least one of the layers is treated with an antistatic material.

10. A charged web having a Nelson bacterial filtration efficiency of at least 96%.

11. The charged web of claim 10 wherein the web is an electrostatically charged web.

12. The charged web of claim 10 wherein the web is a nonwoven web.

13. The charged web of claim 12 wherein the nonwoven web comprises two outer layers separated by an intermediate layer wherein the two outer layers are spunbond nonwoven layers and the intermediate layer is a meltblown layer.

two outer layers separated by an intermediate layer, ³⁰ wherein the two outer layers are spunbond nonwoven layers and the intermediate layer is a meltblown layer; and

14. The charged web of claim 10 containing antistatic material.

15. A web prepared by a process comprising sterilizing a charged web by ethylene oxide sterilization.

16. The web of claim 15 wherein the charged web is an electrostatically charged web.

17. The web of claim 15 wherein the charged web is a nonwoven web.

18. The web of claim 17 wherein the nonwoven web comprises two outer layers separated by an intermediate layer wherein the two outer layers are spunbond nonwoven layers and the intermediate layer is a meltblown layer.

19. The web of claim 15 wherein the process further comprises treatment with an antistatic material.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATION OF CORRECTION

PATENT NO. : 5,814,570

DATED : September 29, 1998

INVENTOR(S): Bernard Cohen

.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, line 30, "squares" should read --squames--; Column 3, line 48, "ethylene" should read --ethylene--; Column 5, line 7, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 8, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 17, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 24-25, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 25, "ZELEC[™] should read --ZELEC®--; Column 5, line 29, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 52, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 58, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 65, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 65, "KIMGUARD[™] should read --KIMGUARD®--; Column 5, line 65, "KIMGUARD[™] should read --KIMGUARD®--; Column 6, line 2, "KIMGUARD[™] should read --KIMGUARD®--; Column 6, line 5, "KIMGUARD[™] should read --KIMGUARD®--; Column 6, line 5, "KIMGUARD[™] should read --KIMGUARD®--;</sup>

Signed and Sealed this

Twentieth Day of April, 1999

K.Jodd Vler

Attest:

Q. TODD DICKINSON

Attesting Officer

.

Acting Commissioner of Patents and Trademarks

.

.